No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Raises Price Target to $45
Cartesian Therapeutics Reports Positive Updated Phase 2b Results in Myasthenia
Express News | Cartesian Therapeutics Inc - Phase 2B Trial Shows 5.5-Point Reduction in Mg-Adl at Month 4
Express News | Cartesian Therapeutics Inc -Safety Profile Consistent With Previously Reported Data and Continues to Support Outpatient Administration
Express News | Cartesian Therapeutics Inc - Phase 3 Aurora Trial to Commence in 1H2025
Express News | Cartesian Therapeutics Announces Positive Updated Results From Phase 2B Trial of Descartes-08 in Participants With Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
No Data